These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27126881)

  • 41. Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.
    Martin JH; Deacon CF; Gorrell MD; Prins JB
    Intern Med J; 2011 Apr; 41(4):299-307. PubMed ID: 21299778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
    de Heer J; Göke B
    Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preserving insulin secretion in Type 2 diabetes mellitus.
    Tibaldi J
    Expert Rev Endocrinol Metab; 2008 Mar; 3(2):147-159. PubMed ID: 30764089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Notable Underlying Mechanism for Pancreatic β-Cell Dysfunction and Atherosclerosis: Pleiotropic Roles of Incretin and Insulin Signaling.
    Kaneto H; Obata A; Kimura T; Shimoda M; Sanada J; Fushimi Y; Katakami N; Matsuoka T; Kaku K
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging role of insulin with incretin therapies for management of type 2 diabetes.
    Ahluwalia R; Vora J
    Diabetes Ther; 2011 Sep; 2(3):146-61. PubMed ID: 22127824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type 2 diabetes mellitus: pathogenesis and genetic diagnosis.
    Himanshu D; Ali W; Wamique M
    J Diabetes Metab Disord; 2020 Dec; 19(2):1959-1966. PubMed ID: 33520871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.
    Saisho Y
    World J Diabetes; 2015 Feb; 6(1):109-24. PubMed ID: 25685282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.
    Jung KY; Kim KM; Lim S
    Diabetes Metab J; 2014 Dec; 38(6):426-36. PubMed ID: 25541605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.
    Saisho Y
    J Clin Med; 2014 Aug; 3(3):923-43. PubMed ID: 26237486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes.
    Inaishi J; Saisho Y
    J Clin Med; 2017 Nov; 6(12):. PubMed ID: 29483484
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Corrigendum to "Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis" [Biomed. Pharmacother. 97 (330-338) 330-338].
    Srivastava S; Shree P; Pandey H; Tripathi YB
    Biomed Pharmacother; 2018 Nov; 107():1795. PubMed ID: 30115498
    [No Abstract]   [Full Text] [Related]  

  • 56. Apoptosis in pancreatic β-islet cells in Type 2 diabetes.
    Tomita T
    Bosn J Basic Med Sci; 2016 Aug; 16(3):162-79. PubMed ID: 27209071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is GLP-1 a hormone: Whether and When?
    D'Alessio D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):50-5. PubMed ID: 27186356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Drugs affecting the incretin system and renal glucose transport: do they meet the expectations of modern therapy of type 2 diabetes?].
    Gumieniczek A
    Postepy Hig Med Dosw (Online); 2016 May; 70():425-34. PubMed ID: 27180961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.
    Zietek T; Rath E
    Front Immunol; 2016; 7():154. PubMed ID: 27148273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.